BackCelyad Oncology Overview

Celyad Oncology Total Liabilities

Latest total liabilities for CYAD: $9.6M.

Get informed when a big investor buys or sells

+ Follow
Total Liabilities
$9.58M
14.14% YoYΔ $-1.58M vs prior year quarter

Peer average

Loading

Celyad Oncology Total Liabilities History

Loading

Celyad Oncology vs. peers: Total Liabilities Comparison

Loading

Celyad Oncology Total Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Celyad Oncology (CYAD) FAQ

As of the most recent data (June 2024), CYAD shows a total liabilities of $9.6M. That compares with $11M in the prior-year period — down 14.1% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, CYAD's total liabilities is now $9.6M (was $11M) — a 14.1% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Celyad Oncology is outperforming or lagging.

Tracking CYAD's total liabilities over time shows whether Celyad Oncology is scaling, shrinking, or reshaping that part of the business. The current reading is $9.6M That compares with $11M in the prior-year period — down 14.1% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this total liabilities page, Stockcircle has Celyad Oncology's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect total liabilities (currently $9.6M) with ownership activity and broader fundamentals.

Celyad Oncology's total liabilities is $9.6M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.